EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

PD‐1 blockade treatment in melanoma: Mechanism of response and tumor‐intrinsic resistance

Tong Wang iD, Wenjie Ma, Zijian Zou, Jingqin Zhong, Xinyi Lin, Wanlin Liu, Wei Sun, Tu Hu, Yu Xu, Yong Chen

Cancer Science · 2025

DOI: 10.1111/cas.16398 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Science, 2025. Verfasst von Tong Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Melanoma, Drug Resistance, Neoplasm, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant melanoma is characterized by high immunogenicity, genetic heterogeneity, and diverse pathological manifestations, affecting both skin and mucosa over the body. Pembrolizumab and nivolumab, both anti‐PD‐1 monoclonal antibodies, were approved by the US FDA for unresectable or metastatic melanoma in 2011 and 2014, respectively, with enduring and transformative outcomes. Despite marked clinical achievements, only a subset of patients manifested a complete response. Approximately 55% of melanoma patients exhibited primary resistance to PD‐1 antibodies, with nearly 25% developing secondary resistance within 2 years of treatment. Thus, there is a critical need to comprehensively elucidate the mechanisms underlying the efficacy and resistance to PD‐1 blockade. This review discusses the fundamental mechanisms of PD‐1 blockade, encompassing insights from T cells and B cells, and presents resistance to anti‐PD‐1 with a particular focus on tumoral‐intrinsic mechanisms in melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaDrug Resistance, NeoplasmProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsSkin NeoplasmsHumansAntibodies, Monoclonal, HumanizedNivolumabAnimalsT-LymphocytesB-Lymphocytes

Stichwörter der Autor:innen

PD‐1 antibodiesfundamental mechanismimmunotherapymelanomaresistance mechanism

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorspembrolizumabAntibodies, Monoclonal, HumanizedPDCD1 protein, humanNivolumab

Autor:innen und Institutionen

  • Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Oncology, Shanghai Medical College, Shanghai, China.

ORCID-Profile: Tong Wang

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Wang, T., Ma, W., Zou, Z., Zhong, J., Lin, X., Liu, W., Sun, W., Hu, T., Xu, Y., & Chen, Y. (2025). PD‐1 blockade treatment in melanoma: Mechanism of response and tumor‐intrinsic resistance. Cancer Science. https://doi.org/10.1111/cas.16398

Vancouver

Wang T, Ma W, Zou Z, Zhong J, Lin X, Liu W, et al. PD‐1 blockade treatment in melanoma: Mechanism of response and tumor‐intrinsic resistance. Cancer Science. 2025. doi:10.1111/cas.16398

BibTeX
@article{Wang2025,
  author = {Wang, Tong and Ma, Wenjie and Zou, Zijian and Zhong, Jingqin and Lin, Xinyi and Liu, Wanlin and Sun, Wei and Hu, Tu and Xu, Yu and Chen, Yong},
  title = {PD‐1 blockade treatment in melanoma: Mechanism of response and tumor‐intrinsic resistance},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.16398}
}
Kostenlos starten →